Navigation Links
IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
Date:8/27/2007

Company's belief that the supplemental data to be submitted in the amended NDA will overcome the need for additional trials, the review of the submissions for marketing approval of L-MTP-PE by the FDA and the EMEA, and the Company's goal of making L-MTP-PE available to patients as quickly as possible. Actual results may differ materially from the forward-looking statements due to a number of important factors, including, but not limited to, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE by the first quarter of 2008, if at all, the possibility that such data will not support the benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the FDA's and EMEA's review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the FDA and EMEA in a satisfactory manner, the time needed to respond to any issues raised by the FDA and EMEA with regard to regulatory submissions for L-MTP-PE, although the FDA is not bound by the decision of any advisory panel, the possible negative impact that the opinion of the FDA's Oncologic Drugs Advisory Committee that the results of the Company's Phase 3 trial do not provide substantial evidence of effectiveness of L-MTP-PE in the treatment of patients with non-metastatic, resectable osteosarcoma receiving combination chemotherapy would have upon the determination by the FDA whether to approve the marketing application for L- MTP-PE, which would have a material and adverse affect on IDM's business, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Ph
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Analyzing Trace-Level Impurities of a Pharmaceutical Intermediate Using an LCQ Deca Ion Trap Mass Spectrometer and the Mass Frontier Software Package
2. Rapid SNP Genotyping of the Pharmacogenomically Important Allele CYP2D6*4 Using Real-Time qPCR on the DNA Engine Opticon 2 System
3. Development of a sensitive enzyme fragment complementation assay for cyclic adenosine 3, 5 monophosphate and its validation for pharmacological screening at G protein-coupled receptors
4. Practical Applications of HyperDSC in a Pharmaceutical Laboratory
5. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
6. Germantown drug company hires pharma veteran James Davidson as COO
7. Deltanoid Pharmaceuticals begins phase II osteoporosis study
8. New angel capital centered on GenTel agreement with big pharma
9. The deconstruction of Big Pharma
10. Big pharma seeks Wisconsin biotech partnerships
11. Doing the pharmaceutical tango
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... May 28, 2015 Glenn Keet, CEO ... Changing Landscape of EMR/EHR Clinical Data Integration with EDC ... place in Washington, DC on June 14th-18th. , During ... integrating EMR/EHR systems with EDC, and will examine the ... by eSource and electronic health records/electronic medical records integration. ...
(Date:5/28/2015)... Rochelle, Virginia (PRWEB) May 28, 2015 ... Partners LLC announced today that Roger L. Williams, ... Expert consultant. NDA Partners Premier Experts are top ... them to bring extraordinary value to the company’s ... critical solutions to help clients successfully develop their ...
(Date:5/27/2015)... RXi Pharmaceuticals Corporation (NASDAQ: RXII ... developing innovative therapies primarily in the areas of ... a public offering of shares of its common ... stock and overallotment purchase rights to purchase shares ... stock, warrants and overallotment purchase rights are immediately ...
(Date:5/27/2015)... May 27, 2015 Expanding in a ... manufacturer Avalon Biomed Inc. recently inked a ... Mokuda Dental Co. Ltd. , the largest endodontic distributor ... the international market for Avalon Biomed, which manufactures Grey ... tricalcium silicate-based dental cements that have won renown from ...
Breaking Biology Technology:Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2Former CEO and Chair of the Council of Experts at the USP, Roger L. Williams, MD, Joins NDA Partners as a Premier Expert Consultant 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 2RXi Pharmaceuticals Announces Proposed Public Offering of Common Stock and Warrants 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3
... de Bono, Peter Gabriel, HRH Prince Hassan, Malcolm McLaren, Carolyn ... Porco and Philippe Starck on judging ... Creative,Director of Saatchi & Saatchi, today announces the contenders to ... Held biennially, this global competition was established by Saatchi ...
... First Clinical Milestone Validates Approach, SAN FRANCISCO, ... completion of its first clinical trial, a,proof-of-concept study ... sodium channel blocker. Rufinamide was discovered and,developed by ... Europe as a,drug to treat a form of ...
... Progentix,Orthobiology B.V. announced today the closure of its ... BioGeneration Ventures., Progentix Orthobiology B.V. was established ... material products for clinical application,in bone regenerative surgery. ... ceramic biomaterial scaffolds that have the ability to,attract ...
Cached Biology Technology:Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 2Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 3Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 4Ten Extraordinary Innovations Line Up For US $100,000 Saatchi & Saatchi Award For World Changing Ideas 5Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 2Synosia Announces Encouraging Results of Proof-of-Concept Clinical Trial for Epilepsy Drug rufinamide as a Treatment for Mood Disorders 3Progentix Orthobiology B.V. Closes Series A Financing Round 2
(Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
(Date:5/22/2015)... May 22, 2015 According to ... Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, Databases), ... and Utilities, Consumer and Home) - Global Forecast to ... from $2.77 Billion in 2015 to $6.19 Billion by ... Browse 79 market data Tables and   43 Figures ...
(Date:5/20/2015)... , May 20, 2015 NXT-ID, Inc. (NASDAQ: ... its wholly owned subsidiary, 3D-ID LLC, a company engaged ... Battelle for the biometrics technology portion of the recently ... from the Department of the Army. 3D-ID ... developed for government, law enforcement and security agencies. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... policymakers to encourage the transition from coal-based electricity production to ... Such a mechanism would help limit carbon dioxide (CO ... in Copenhagen last December, the United States pledged to reduce ... percent by 2020. Dagobert Brito, the George A. ...
... DURHAM, N.C. -- Faced with threats such as habitat ... worldwide may become extinct before scientists can even discover them, ... American and British researchers in the journal Proceedings of ... overall, there could be between 5 million and 50 million ...
... NC In its early stages, prostate cancer requires ... male sex characteristics) for growth, and current first-line therapies ... development and spread. However, advanced prostate ... ineffective. Scientists aren,t sure how this shift occurs ...
Cached Biology News:Researchers calculate the cost of CO2 emissions, call for carbon tax 2Thousands of undiscovered plant species face extinction 2UNC team finds new target for treatment of advanced prostate cancer 2
... (MSTA) slides were designed to study protein expression ... species. Tissue slices from three different species ... then be treated as a single histological slide ... hybridization. This format allows a rapid ...
... Pulser Xcell eukaryotic system, 100 ... is used for electroporation of ... the main unit, CE module ... or square-wave pulses, ShockPod shocking ...
... is used to predict the ... sequence up to 3,200 bases, ... of primers and GC clamps ... gradient gel electrophoresis (DGGE), constant ...
AVOID FREEZE/THAW CYCLES. Recognizes the ~5 kDa thymosin beta4 protein....
Biology Products: